Related Experiment Video
Updated: Jun 19, 2026
05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
Weight-loss dynamics with tirzepatide versus semaglutide
A J Venkatakrishnan1, Karthik Murugadoss1, Venky Soundararajan1
1Metabolism Agentic Intelligence Atlas (MAIA), nference, 1 Main Street, East Arcade Building, Cambridge, MA 02142, USA.
PNAS Nexus
|June 18, 2026
Summary
Tirzepatide led to greater and faster weight loss than semaglutide in a large real-world study. Demographic variations in response highlight the need for personalized incretin therapy in obesity and type 2 diabetes management.
Area of Science:
- Pharmacology
- Endocrinology
- Obesity Medicine
Background:
- Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are established treatments for obesity and type 2 diabetes.
- Significant inter-individual variability exists in weight-loss outcomes with GLP-1RAs, necessitating further investigation into contributing factors.
Purpose of the Study:
- To compare the efficacy and safety of tirzepatide and semaglutide in a real-world setting.
- To analyze demographic variations in treatment response to these incretin therapies.
Main Methods:
- Retrospective cohort study utilizing de-identified electronic health records.
- 1:1 propensity score matching of 10,339 tirzepatide-treated and 10,339 semaglutide-treated patients.
- AI-enabled curation of clinical notes for adverse event identification.
Main Results:
- Tirzepatide demonstrated significantly greater mean weight reduction (14.7%) compared to semaglutide (10.8%).
- Higher rates of significant weight loss (≥15% in year 1) were observed with tirzepatide (42.6% vs. 21.6%).
- Tirzepatide was associated with fewer gastrointestinal and systemic adverse events; demographic disparities in weight loss were noted across both treatments.
Conclusions:
- Tirzepatide is associated with superior weight loss compared to semaglutide in a real-world, propensity-matched cohort.
- Observed demographic variations in treatment response underscore the need for personalized approaches in incretin therapy.
- Findings support the integration of real-world evidence into clinical trial design and routine care for obesity and type 2 diabetes.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...